CRISPR THERAPEUTICS AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.08 USD | +1.84% |
|
+4.14% | -10.32% |
| Apr. 18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
| Apr. 17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
Presenter SpeechTabassum Ahsan (Attendees)I'm Taby Ahsan, Vice President of Cell and Gene Ther...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
55.07
USD
Average target price
88.12
USD
Spread / Average Target
+60.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.32% | 4.67B | |
| +23.29% | 48.09B | |
| +46.90% | 40.62B | |
| -2.96% | 40.43B | |
| -6.20% | 28.36B | |
| +9.24% | 24.89B | |
| -19.77% | 19.01B | |
| +29.51% | 12.09B | |
| +0.74% | 11.88B | |
| -1.10% | 11.8B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- Transcript : CRISPR Therapeutics AG - Special Call
